J&J's Doxil fixes put Sun Pharma's supply deal in jeopardy

Sun Pharmaceutical Industries shares fell on worries that the Indian drugmaker will lose a contract to sell its version of the cancer drug Doxil in the U.S., after Johnson & Johnson ($JNJ) said it would resume supplying the scarce drug. Report

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.